Skip to main content
ARGX
NASDAQ Life Sciences

ARGENX Receives FDA Priority Review for VYVGART sBLA in Seronegative gMG, Targeting Expanded Patient Population

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$813.3
Mkt Cap
$48.494B
52W Low
$510.055
52W High
$934.62
52W Position info
59% above low
Off High info
13% below high
Rel. Volume info
1.4× avg
Market data snapshot near publication time

ARGX sits 59% above its 52-week low of $510.055.

Summary

ARGENX announced the FDA has granted priority review for its supplemental Biologics License Application for VYVGART in AChR-Ab seronegative generalized myasthenia gravis, with a PDUFA date of May 10, 2026.


Key Events · Product Development and Regulatory · ARGX

  • FDA Accepts sBLA with Priority Review

    The U.S. Food and Drug Administration (FDA) has accepted for priority review a supplemental Biologics License Application (sBLA) for VYVGART (efgartigimod alfa-fcab) for the treatment of adults with AChR-Ab seronegative generalized myasthenia gravis (gMG).

  • PDUFA Target Action Date Set

    A Prescription Drug User Fee Act (PDUFA) target action date of May 10, 2026, has been set for the sBLA.

  • Supported by Positive Phase 3 Data

    The sBLA is supported by data from the Phase 3 ADAPT SERON study, which met its primary endpoint, demonstrating statistically significant improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) total score compared to placebo.

  • Addresses Unmet Medical Need

    This expanded indication aims to provide a much-needed treatment option for seronegative gMG patients, who currently face limited therapeutic choices.


Analysis · ARGX · Life Sciences

The FDA's acceptance of the supplemental Biologics License Application (sBLA) for VYVGART with Priority Review is a significant positive development for ARGENX. This accelerates the potential approval timeline for an expanded indication, addressing a critical unmet medical need in acetylcholine receptor antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG) patients. The positive Phase 3 ADAPT SERON study data supporting the sBLA further de-risks the approval process and positions VYVGART to capture a broader market segment, potentially driving future revenue growth for the company.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ARGX was trading at $813.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $48.5B. The 52-week trading range was $510.06 to $934.62. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ARGX - Latest Insights

ARGX
Nov 09, 2026, 8:01 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $945.64
Real-time Price: $981.33 info
Change: +$35.69 (+4%) info
Market Cap: $61.034B info
ARGX
Nov 09, 2026, 6:01 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $894.64
Real-time Price: $981.33 info
Change: +$86.69 (+10%) info
Market Cap: $61.034B info
ARGX
Oct 22, 2026, 8:20 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $854.00
Real-time Price: $981.33 info
Change: +$127.33 (+15%) info
Market Cap: $61.034B info
ARGX
Oct 08, 2026, 6:51 AM EDT
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $795.20
Real-time Price: $981.33 info
Change: +$186.13 (+23%) info
Market Cap: $61.034B info
ARGX
Oct 08, 2026, 6:01 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $791.00
Real-time Price: $981.33 info
Change: +$190.33 (+24%) info
Market Cap: $61.034B info